About: Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session
Creator	Liu, Jing Agarwala, Anandita Al Rifai, Mahmoud Gulati, Martha Jia, Xiaoming Virani, Salim
Source	Medline; PMC
abstract	PURPOSE OF REVIEW: The review highlights selected studies related to cardiovascular disease (CVD) prevention that were presented at the American College of Cardiology 2020 Virtual Scientific Session (ACC.20)/World Cardiology Congress (WCC). RECENT FINDINGS: The studies reviewed include clinical trials on the efficacy and safety of alirocumab (Study in Participants with Homozygous Familial Hypercholesterolemia [ODYSSEY HoFH]) and evinacumab in the treatment of homozygous familial hypercholesterolemia (HoFH); Evaluating the Efficacy of E-cigarettes for Smoking Cessation (E3); the use of renal denervation in the treatment of hypertension (SPYRAL HTN-OFF MED PIVOTAL); and the assessment of vericiguat in the treatment of heart failure (A Study of Vericiguat in Participants with Heart Failure with Reduce Ejection Fraction [VICTORIA]). In addition, results from the pooled analysis of phase III trials on inclisiran and secondary analysis examining eicosapentaenoic acid levels and cardiovascular outcomes from the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) were included. Finally, we discuss studies examining the use of polygenic risk score with low density lipoprotein cholesterol (LDL-C) and systolic blood pressure (SBP) on lifetime cardiovascular risk. SUMMARY: The studies presented at the ACC.20/WCC represent notable contributions in the field of CVD prevention.
has issue date	2020-06-18(xsd:dateTime)
bibo:doi	10.1007/s11883-020-00856-6
bibo:pmid	32556778
has license	no-cc
sha1sum (hex)	d6a1cf16e038cc4df07deec6b7e6abb0a6a6749c
schema:url	https://doi.org/10.1007/s11883-020-00856-6
resource representing a document's title	Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session
has PubMed Central identifier	PMC7301047
has PubMed identifier	32556778
schema:publication	Curr Atheroscler Rep
resource representing a document's body	covid:d6a1cf16e038cc4df07deec6b7e6abb0a6a6749c#body_text
is schema:about of	named entity 'studies' named entity 'Purpose' named entity 'Cardiovascular Disease' named entity 'USE OF' named entity 'SMOKING CESSATION' named entity 'Participants' named entity 'selected' named entity 'ACC' named entity 'Congress' named entity 'studies' named entity 'Cardiology' named entity 'heart failure' named entity 'World' named entity 'Ejection Fraction' named entity 'Smoking Cessation' named entity 'alirocumab' named entity 'Heart Failure' named entity 'CVD' named entity 'CAD' named entity 'heart failure' named entity 'EPA' named entity 'SBP' named entity '10.8' named entity 'renal artery' named entity 'LDL-C' named entity 'cholesterol' named entity 'HDL-C' named entity 'icosapent' named entity 'inclisiran' named entity 'A1c' named entity 'LDL-C' named entity 'American College of Cardiology' named entity 'heart failure' named entity 'cutaneous' named entity 'heterogeneity' named entity 'randomized controlled trial' named entity 'ezetimibe' named entity 'ethyl' named entity 'angiotensin receptor blocker' named entity 'long-term' named entity 'placebo' named entity 'LDLRAP1' named entity 'cardiologists' named entity '26.1' named entity 'cardiovascular mortality' named entity 'clinical setting' named entity 'long-term' named entity 'SBP' named entity 'placebo' named entity 'mutation' named entity 'PCSK9 inhibitor' named entity 'long-term health effects' named entity 'APOB' named entity 'LDL-C' named entity 'primary prevention' named entity 'LDLR' named entity 'antihypertensive' named entity 'SBP' named entity 'smoking cessation' named entity 'lifetime risk' named entity 'endothelial lipase' named entity 'medical therapy' named entity 'icosapent' named entity 'serum' named entity 'long-term' named entity 'icosapent' named entity 'ejection fraction' named entity 'Department of Veterans Affairs' named entity 'kidney' named entity 'relative risk' named entity 'lifetime risk' named entity 'placebo' named entity 'ambulatory blood pressure monitoring' named entity 'EPA' named entity 'placebo group' named entity 'hematologic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software